The 40:1 ratio contains 2.5-fold more d-chiro-inositol than the physiological ovarian requirement (100:1), creating relative DCI excess that impairs oocyte quality, increases FSH requirements, and can block aromatase activityโ€”making it suboptimal for fertility outcomes particularly in assisted reproduction, despite effectiveness for restoring ovulation in insulin-resistant anovulatory patients.

The available evidence suggests the 40:1 myo-inositol to d-chiro-inositol (MI/DCI) ratio demonstrates context-dependent efficacy rather than being universally โ€œwrongโ€ for PCOS and fertility. The ratio appears effective for restoring ovulation in anovulatory, insulin-resistant patients seeking natural conception, but multiple lines of evidence indicate it may be suboptimal for oocyte quality during assisted reproduction. Head-to-head comparisons consistently favor MI over DCI for fertility outcomes in ART contexts, with Isabella et al. demonstrating dose-dependent deterioration in oocyte quality, embryo quality, and FSH requirements as DCI doses increase from 300 to 2400 mg. Mechanistically, the physiological ovarian MI/DCI ratio is 100:1โ€”approximately 2.5-fold higher than the 40:1 ratio used in supplementsโ€”suggesting the 40:1 formulation contains excessive DCI relative to ovarian tissue requirements. The โ€œD-chiro-inositol ovarian paradoxโ€ explains that increased epimerase activity in PCOS ovaries already creates local MI deficiency, which exogenous DCI at 40:1 may exacerbate rather than correct. Furthermore, high DCI doses can block aromatase expression and paradoxically cause hyperandrogenism, potentially impairing fertility despite systemic metabolic benefits. However, the evidence does not conclusively prove 40:1 is wrong for all PCOS patients: it may represent an acceptable compromise for anovulation when systemic insulin sensitization is needed, but appears excessive for euglycemic patients or those prioritizing oocyte quality in assisted reproduction, where ratios approaching the physiological 100:1 may be preferable.

Read the full report here:ย Why 40:1 myo-inositol to d-chiro Inositol is wrong for PCOS and Fertility

References

M. Nordio, S. Basciani, E. Camajani

(2019). The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. European Review for Medical and Pharmacological Sciences

A. Pizzo, A. Laganร , L. Barbaro

(2014). Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecological Endocrinology

V. Unfer, G. Carlomagno, P. Rizzo, E. Raffone, S. Roseff

(2011). Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. European Review for Medical and Pharmacological Sciences

R. Isabella, E. Raffone

(2012). CONCERN: Does ovary need D-chiro-inositol?. Journal of Ovarian Research

M. Showell, Rebecca Mackenzie-Proctor, V. Jordan, Ruth Hodgson, C. Farquhar

(2016). Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews

V. Unfer, J. Nestler, Z. Kamenov, N. Prapas, F. Facchinetti

(2016). Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. International Journal of Endocrinology

J. Nestler, D. Jakubowicz, Paula Reamer, R. Gunn, G. Allan

(1999). Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. New England Journal of Medicine

N. Mendoza, Laura M. Pรฉrez, T. Simoncini, A. Genazzani

(2017). Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biomedicine Online

A. Laganร , A. Vitagliano, M. Noventa, G. Ambrosini, R. Dโ€™Anna

(2018). Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Archives of Gynecology and Obstetrics

O. Pustotina, Samuel H Myers, Vittorio Unfer, Irina Rasulova

(2024). The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. Gynecologic and Obstetric Investigation